IL266087B2 - Use of itolizumab to reduce phosphorylation of cd6 - Google Patents
Use of itolizumab to reduce phosphorylation of cd6Info
- Publication number
- IL266087B2 IL266087B2 IL266087A IL26608719A IL266087B2 IL 266087 B2 IL266087 B2 IL 266087B2 IL 266087 A IL266087 A IL 266087A IL 26608719 A IL26608719 A IL 26608719A IL 266087 B2 IL266087 B2 IL 266087B2
- Authority
- IL
- Israel
- Prior art keywords
- alcam
- antibody
- itolizumab
- phosphorylation
- complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Electrically Operated Instructional Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641035602 | 2016-10-18 | ||
| PCT/IB2017/056403 WO2018073721A1 (en) | 2016-10-18 | 2017-10-16 | Use of itolizumab to reduce phosphorylation of cd6 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL266087A IL266087A (en) | 2019-06-30 |
| IL266087B1 IL266087B1 (en) | 2023-10-01 |
| IL266087B2 true IL266087B2 (en) | 2024-02-01 |
Family
ID=62019244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266087A IL266087B2 (en) | 2016-10-18 | 2017-10-16 | Use of itolizumab to reduce phosphorylation of cd6 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190248913A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3528846A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7065085B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102469798B1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017345390B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3076861A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL266087B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018073721A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2993186T (pt) | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| US10189899B2 (en) | 2013-07-23 | 2019-01-29 | Biocon Limited | Use of a CD6 binding partner and method based thereon |
| KR102514528B1 (ko) | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
| WO2019169015A1 (en) * | 2018-02-27 | 2019-09-06 | Equillium, Inc. | Anti cd6 antibodies for treating severe asthma |
| US20230076643A1 (en) * | 2019-12-30 | 2023-03-09 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113083A1 (en) * | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| WO2015011658A1 (en) * | 2013-07-23 | 2015-01-29 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102514528B1 (ko) * | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
| US20230151107A1 (en) * | 2020-04-04 | 2023-05-18 | Biocon Limited | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 |
-
2017
- 2017-10-16 IL IL266087A patent/IL266087B2/en unknown
- 2017-10-16 EP EP17862860.8A patent/EP3528846A4/en active Pending
- 2017-10-16 CA CA3076861A patent/CA3076861A1/en active Pending
- 2017-10-16 AU AU2017345390A patent/AU2017345390B2/en active Active
- 2017-10-16 KR KR1020197014350A patent/KR102469798B1/ko active Active
- 2017-10-16 JP JP2019520731A patent/JP7065085B2/ja not_active Expired - Fee Related
- 2017-10-16 WO PCT/IB2017/056403 patent/WO2018073721A1/en not_active Ceased
-
2019
- 2019-04-17 US US16/387,442 patent/US20190248913A1/en not_active Abandoned
-
2023
- 2023-06-15 US US18/335,542 patent/US20240101700A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113083A1 (en) * | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| WO2015011658A1 (en) * | 2013-07-23 | 2015-01-29 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
Non-Patent Citations (4)
| Title |
|---|
| A IRA ET AL.,, IMMUNOLOGICAL AND HISTOLOGICAL EVALUATION OF CLINICAL SAMPLES FROM PSORIASIS PATIENTS TREATED WITH ANTI- CD 6 ITOLIZUMAB, 1 May 2014 (2014-05-01) * |
| HASSAN ET AL.,, CD 6 REGULATES T- CELL RESPONSES THROUGH ACTIVATION-DEPENDENT RECRUITMENT OF THE POSITIVE REGULATOR SLP-76, 1 September 2006 (2006-09-01) * |
| NAIR P ET AL,, CD6 SYNERGISTIC CO-STIMULATION PROMOTING PROINFLAMMATORY RESPONSE IS MODULATED WITHOUT INTERFERING WITH THE ACTIVATED LEUCOCYTE CELL ADHESION MOLECULE INTERACTION, 19 August 2010 (2010-08-19) * |
| RONCAGALLI ET AL.,, QUANTITATIVE PROTEOMIC ANALYSIS OF SIGNALOSOME DYNAMICS IN PRIMARY T CELLS IDENTIFIES THE CD 6 SURFACE RECEPTOR AS A LAT-INDEPENDENT TCR SIGNALING HUB, 2 March 2014 (2014-03-02) * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102469798B1 (ko) | 2022-11-22 |
| KR20190070957A (ko) | 2019-06-21 |
| EP3528846A1 (en) | 2019-08-28 |
| EP3528846A4 (en) | 2020-06-03 |
| US20190248913A1 (en) | 2019-08-15 |
| WO2018073721A1 (en) | 2018-04-26 |
| AU2017345390A1 (en) | 2019-05-02 |
| IL266087B1 (en) | 2023-10-01 |
| US20240101700A1 (en) | 2024-03-28 |
| JP2020504597A (ja) | 2020-02-13 |
| AU2017345390B2 (en) | 2024-08-08 |
| JP7065085B2 (ja) | 2022-05-11 |
| IL266087A (en) | 2019-06-30 |
| CA3076861A1 (en) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240101700A1 (en) | Use of itolizumab to reduce phosphorylation of cd6 | |
| US20220193199A1 (en) | Il-15 and il-15ralpha sushi domain based modulokines | |
| JP7565678B2 (ja) | 組合せ医薬組成物 | |
| Bloemendaal et al. | Anti–tumor necrosis factor with a glyco-engineered Fc-region has increased efficacy in mice with colitis | |
| KR20200034958A (ko) | 암 요법에서 면역 관련된 유해 사례를 치료하기 위한 가용성 cd24의 사용 방법 | |
| US20220227880A1 (en) | Monoclonal antibody and a method of use for the treatment of lupus | |
| HK40074884A (en) | Il-15 and il-15ralpha sushi domain based on modulokines | |
| HK40102087A (en) | Il-15 and il-15ralpha sushi domain based on modulokines | |
| HK40074884B (en) | Il-15 and il-15ralpha sushi domain based on modulokines | |
| HK40004449A (en) | Il-15 and il-15raplha sushi domain based modulokines | |
| HK40004449B (en) | Il-15 and il-15ralpha sushi domain based modulokines |